Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Deferred Revenue (Non-current)
Payments received for goods or services the company will deliver after more than one year.
Alumis Inc. Common StockNASDAQ: ALMS
Deferred Revenue (Non-current) · Q2 FY2026 · quarter ended Jun 2026
Deferred revenue (non-current) remains negative
Q2 FY2026 deferred revenue (non-current) was $0, compared with $2.61M a year earlier.
Context
- Deferred revenue (non-current) amounted to 0.0% of total assets at the end of Q2 FY2026, down 0.4 pp from a year earlier.
- Deferred revenue (non-current) increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether deferred revenue (non-current) keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue (Non-current) history
USD · from the balance sheet
- Latest · FY2025
- 2.61M USD
- Year-over-year change
- —
| Period | Period end | Deferred Revenue (Non-current) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.61M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Deferred Revenue (Non-current) vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred revenue (non-current) is compared through growth and share of total assets rather than absolute size.
- Deferred revenue (non-current) amounts to 0.0% of total assets for ALMS, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $15.29M USD | — | — | 7.7% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $0 USD | -100.0% | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €0 EUR | — | — | 0.0% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | €0 EUR | — | — | 0.0% | |
| Dec 2025 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | — | — | 0.0% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.